05/05/2026
"FY26 has been a year of consistent outperformance, marked by our ability to navigate challenges while building a more purpose‑led and performance‑oriented organization,” Ashok Nair, MD RPG Life Sciences Ltd. highlighted while reflecting on the year gone by.
Despite external headwinds, RPG Life Sciences exited FY26 with strong momentum, led by the Domestic Formulations business, which grew 1.6× faster than the Indian Pharmaceutical Market for the full year. The continued scaling of textbook brands, along with the expansion of chronic and specialty portfolios, is driving meaningful top‑line growth.
In the API business, the focus remains on operational recovery and new customer development to unlock global opportunities, while ongoing digital transformation initiatives are strengthening compliance and productivity across the organization.
Overall, RPG Life Sciences is well‑positioned to deliver sustained growth in FY27, supported by its seven strategic pillars, a robust M&A framework, and continued expansion of manufacturing capabilities.
